Compare AbCellera Biologics Inc (ABCL) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs DoorDash Inc — how do they compare? AbCellera Biologics Inc trades at $10.25 (market cap $2.99B), while DoorDash Inc trades at $212.03 (market cap $91.86B). The key difference: DoorDash Inc is far larger — about 30.7× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | DASH | |
|---|---|---|
Market Cap | $2.99B | $91.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $281.74 |
52-Week Low | $2.78 | $146.60 |
Enterprise Value | $2.58B | $89.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
DoorDash (DASH) trades at $212.24, up 1.13% today, with a bullish technical outlook as it trades near resistance at $215. The company reported strong revenue growth of 36% year-over-year in Q2 2026 to $4.45 billion, though earnings of $0.46 per share missed estimates due to higher R&D costs. Recent news highlights strategic moves like reincorporation in Nevada and insider selling by a director.
The outlook remains positive with a consensus price target of $247.41, representing 16.6% upside, supported by 76% analyst buy ratings. Key risks include execution on AI and autonomous delivery investments, competitive pressures, and margin compression from rising costs. Revenue growth and expanding market share present the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
